<DOC>
	<DOCNO>NCT00652340</DOCNO>
	<brief_summary>This study compare anti-tumor efficacy apricoxib erlotinib placebo erlotinib measure time disease progression test hypothesis regulation COX-2 EGFR pathways patient up-regulated COX-2 expression tumor clinical benefit compare erlotinib alone .</brief_summary>
	<brief_title>APRiCOT-L : Study Evaluate Efficacy Safety Apricoxib With Erlotinib Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Pathologically determine Stage IV NSCLC include Stage IIIb ( pleural effusion ) Failed least one prior platinumbased chemotherapy Stage IIIb Stage IV NSCLC . Patients receive platinumbased chemotherapy give adjuvant set eligible . Measurable disease RECIST Greater equal 18 year age ECOG PS 0 1 Radiation therapy within 2 week ; chemotherapy within 3 week ; noncytotoxic investigational agent within 4 week initiate study treatment Evidence NYHA class III great cardiac disease History MI , stroke , ventricular arrhythmia , symptomatic conduction abnormality within 12 month Known HIV infection AIDS Symptomatic CNS metastases Pregnant nursing woman Hypersensitivity intolerance erlotinib , sulfonamide , aspirin , NSAIDs . History upper GI bleeding , ulceration , perforation Prior history COX2 inhibitor therapy treatment metastatic NSCLC Previous antiEGFR kinase therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>